EMEA-001268-PIP01-12-M05
Key facts
| Invented name |
Repatha
|
| Active substance |
Evolocumab
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/0104/2018
|
| PIP number |
EMEA-001268-PIP01-12-M05
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Amgen Europe B.V
Tel. +44 (0)1223 420305
E-mail: medinfointernational@amgen.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001268-PIP01-12-M05
|
| Compliance opinion date |
24/06/2022
|
| Compliance outcome |
positive
|